SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF GEFITINIB IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN CHINA

被引：1
|
作者：
Hu, C. [1 ]
Huang, L. [1 ]
Zhao, D. [1 ]
Xu, L. [1 ]
机构：
[1] Astrazeneca China, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1183
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN166
引用
下载
收藏
页码：A459 / A459
页数：1
相关论文
共 50 条
  • [1] Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
    Araki, Takuya
    Yashima, Hideaki
    Shimizu, Kimihiro
    Aomori, Tohru
    Hashita, Tadahiro
    Kaira, Kyoichi
    Nakamura, Tomonori
    Yamamoto, Koujirou
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [2] Effectiveness and cost of gefitinib in advanced/metastatic non-small cell lung cancer
    Selvi-Sabater, P.
    Sanchez-Martinez, I.
    Sadyrbaeva-Dolgova, S.
    Portillo-Haro, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 289 - 289
  • [3] Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
    Ding, Haiying
    Xin, Wenxiu
    Tong, Yinghui
    Sun, Jiao
    Xu, Gaoqi
    Ye, Ziqi
    Rao, Yuefeng
    PLOS ONE, 2020, 15 (09):
  • [4] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [5] A REVIEW OF COST-EFFECTIVENESS STUDIES OF PEMBROLIZUMAB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Qiao, N.
    Insinga, R.
    Burke, T.
    Lopes, G.
    VALUE IN HEALTH, 2020, 23 : S41 - S42
  • [6] A COMPARATIVE CLINICAL AND COST-EFFECTIVENESS EVALUATION OF GEFITINIB AND ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Lopes, Gilberto D. L., Jr.
    Segel, Joel
    Tan, Daniel
    Do, Young
    Mok, Tony
    Finkelstein, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1306 - S1307
  • [7] Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review
    Murphy, Mark
    Stordal, Britta
    DRUG RESISTANCE UPDATES, 2011, 14 (03) : 177 - 190
  • [8] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [9] Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
    Cheng, Minyu
    Shao, Yanfei
    Li, Li
    Jiang, Menglao
    Song, Zhouye
    BMC CANCER, 2024, 24 (01)
  • [10] Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
    Minyu Cheng
    Yanfei Shao
    Li Li
    Menglao Jiang
    Zhouye Song
    BMC Cancer, 24
12345